Home > News > Content
Effect Of Indirubin And Its Effect
Jul 12, 2016


This entry may involve the use of drugs, online any advice on the use of drugs can not replace the doctor's advice.

Drug, there are anti-cancer effects, clinical use for the treatment of chronic myeloid leukemia.

Chinese name


Name of foreign language




molecular weight

Two hundred and sixty-two point two six two eight

Molecular formula


brief introduction


Chinese Name: indirubin

2- (2-) -1H- (-3-) - B () - -1H- - () - -3- - (-) - red chip; shell - tree base

English Name: Indirubin

English alias: Red C.I.; Indigo 73200; Indirubin; -1h-indol-3-one (2-oxo-1h-indol-3-ylidene) 2-; (2Z) -2,3'-biindole-2', 3 (1H, 1'H) -dione; 2,3'-biindole-2', 3 (1H, 1'H) -dione

CAS number: 479-41-4

Molecular formula: C16H10N2O2

Molecular weight: 262.2628

Physical and chemical properties


Properties: dark red needle like crystals.

Solubility: soluble in ethyl acetate, acetone, chloroform, ether, insoluble in water, slightly soluble in ethanol.

The molecular formula of indirubin

Density: 1.417g/cm3

Boiling point: 496.6 degrees at C 760 mmHg

Flash point: 207 ~ C

Vapor pressure: at 5.34E-10mmHg 25 degrees C

Use: there are anti-cancer effects, clinical use for the treatment of chronic myeloid leukemia.

Indications: it is used for the treatment of CML chronic phase patients, there are few reports preliminary view is that this product to reduce the associated with splenomegaly of bone marrow fibrosis in patients with spleen may also have a certain effect.

Usage and dosage: adult commonly used amount daily 50 ~ 300mg, the average daily 200mg, 3 ~ 4 times oral, to ease or 3 months for 1 courses. After remission need for long-term use, specific dose still need further exploration, if the services of this product is not valid or effective may consider use of other anti CML drugs.

Preparation and specifications: Indirubin Tablets: 25mg; 50mg; 100mg.

Drug classification: antitumor drugs - other antitumor drugs and adjuvant drugs for the treatment of cancer.



1 pharmacological action:

1.1 indirubin is antileukemia active ingredients isolated from the traditional Chinese medicine indigo (Indigofera tinctoria L.), a pair of indole antitumor drugs. This product has inhibitory effect on many kinds of transplanted animal tumor. It can destroy the leukemia cells. Under the action of this product, the degeneration and necrosis of the cells showed swelling and necrosis. Experimental studies have found that the product can enhance the phagocytic ability of the animal's mononuclear macrophage system. This product had no direct effect on protein synthesis, the inhibition of DNA synthesis was due to the inhibition of DNA polymerase, which affected the polymerization of DNA.

1.2 in vivo process: to mice after taking this product, the blood concentration gradually increased, 12 hours to reach the peak, slow down after January, to maintain a longer time. In the body, the liver, gallbladder, stomach and intestines were the highest, and the bioavailability was 46.48%. Intravenous or oral administration of this product is in the liver and gallbladder metabolism, 96 hours after administration to the feces discharged 76.03%.

2 clinical applications

2.1 is mainly used for chronic myelogenous leukemia (CML). The total effective rate was 87.3% and the white cell function and busulfan similar, reduced liver curative effect is better than busulfan, but hemogram and myelogram in mitigation effect than busulfan difference, with busulfan without cross resistance.

2.2 can be used for abnormal bone marrow hyperplasia and eosinophilic.

matters needing attention


1 the following caution: liver, kidney, heart dysfunction, gastrointestinal ulcer or active inflammatory lesions.

2 long-term use of this product to consolidate the efficacy should be followed by a regular follow-up of cardiovascular changes, such as abnormal cardiovascular or ECG showed that the performance should be considered to stop serving the product.

3 the use of the product dose, often according to the patient's tolerance and efficacy and regulation.

4 as in the medication process appeared severe diarrhea, abdominal pain, hematochezia, vomiting, intussusception, headache and cardiovascular abnormal phenomenon should be discontinued immediately; discontinued due to adverse reactions of shall be close observation of the disease, to take corresponding treatment and make differential diagnosis.

5 if CML patients take this product has reached 6 to 8 weeks and clinical and blood or bone marrow like showed no significant improvement, consider to stop taking this product, switch to the other treatment.

6 although yet to see about taking the product of fetal health and safety of data, but taking into account the and other types of this product may be similar antitumor drugs, may interfere with fetal growth or mutagenic, teratogenic effects, so it should be avoided in pregnancy or lactation choose this product.

7 adverse reactions

7.1 common severity of abdominal pain, periumbilical pain, otherwise mild nausea, vomiting, defecate number increase and tenesmus gastrointestinal reaction, a few serious adverse reactions had hematochezia, most of the gastrointestinal tract reaction to stop drug namely disappear.

7.2 individual patients can reduce the incidence of white blood cells, bone marrow suppression.

7.3 individual patients in long-term medication after 2 ~ 3 years have chest tightness, shortness of breath, heart enlargement, pulmonary artery increased width, ECG showed right axis deviation, pulmonary P wave, pulmonary hypertension and other cardiovascular anomalies, after discontinuation of the drug is removed.

7.4 other individuals appear headache, face and leg swelling, insomnia, joint pain, bone pain, cough, liver function damage and intussusception.

8 taboos: liver and kidney dysfunction with caution.

Shaanxi green clean Biological Engineering Co., Ltd.